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S U M M A R Y
Objective: The widespread use of antibiotics in humans and animals has contributed to growing rates of
antibiotic resistance. Previously treatable bacterial infections now require the last line of antibiotics or
are untreatable. The current antibiotic of last resort for carbapenem-resistant Gram-negative bacterial
infections is often colistin. Evidence for the shifting pattern of colistin resistance and how the
international community should respond are discussed in this review.
Methods: The literature on colistin resistance was reviewed.
Results: Plasmid-mediated colistin resistance encoded by mcr-1 was ﬁrst documented in China during
the routine surveillance of food animals. This has been followed by similar reports across a wide
geographic area, in humans, animals, and the environment. The mcr-1 gene has been reported among
human isolates in 29 countries, related to environmental samples in four countries, and in food animals
and other animals in 28 countries. More recently, a second gene encoding resistance, mcr-2, has been
isolated from porcine and bovine Escherichia coli.
Conclusion: The emergence and horizontal transmission of colistin resistance highlights the need for
heightened stewardship efforts across the One Health platform for this antibiotic of last resort, and
indeed for all antibiotics used in animals and humans.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Over the 74 years since the introduction of penicillin, our use
and misuse of antibiotics in humans and animals has led to rising
antibiotic resistance – to such an extent, that once commonly
treatable bacteria are now either untreatable or require the last
line of antibiotics.1,2 [1_TD$DIFF] The movement of resistance genes between
different bacterial species through plasmid-mediated horizontal
gene transfer increases the variety of bacterial populations
possessing multidrug-resistant (MDR) potential, and the intense
selection pressure exerted by antibiotics selects out antibiotic-
resistant bacteria capable of causing infection in humans and
animals.3* Corresponding author. Tel.: +966 13 877 3524; fax: +966 13 877 3790.
E-mail addresses: jaffar.tawﬁq@aramco.com, jaltawﬁ@yahoo.com
(J.A. Al-Tawﬁq).
http://dx.doi.org/10.1016/j.ijid.2016.11.415
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The recent identiﬁcation of new plasmid-mediated resistance
genes conferring colistin resistance in bacterial isolates from food
animals has re-ignited the debate concerning the contribution of
antibiotic consumption in animals to levels of resistance in
humans.4 Although pertinent to all antibiotics, resistance to
colistin is of particular concern as it plays the role of ‘antibiotic
of last resort’ against common Gram-negative bacterial infections
that are now increasingly MDR.5 The shift in patterns of colistin
resistance and how we should respond are examined and
discussed in this review.
2. Colistin resistance
2.1. Measuring colistin resistance
Measurements of in vitro colistin resistance by disk diffusion,
Etest, and agar dilution have a number of important limitations,
chief amongst which are high error rates, low reproducibility, andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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considered the reference standard for polymyxin susceptibility
testing. The Etest, agar dilution, and brothmicrodilution assays are
generally concordant, although discordance of Etest and agar
dilution with broth microdilution has been reported.14,15 Auto-
mated antimicrobial susceptibility testing includes Vitek 2 (Vitek
2 XL; bioMe´rieux, Hazelwood, MO, USA), MicroScan (MicroScan
WalkAway 96 Plus; Siemens Healthcare Diagnostics Inc., Deerﬁeld,
IL, USA), and Etest (Etest; bioMe´rieux SA, Marcy l’Etoile, France)
assays. Compared to agar dilution, Vitek 2 and Etest show excellent
agreement for the testing of colistin resistance in Acinetobacter.16
Deﬁnite breakpoints for colistin susceptibility have been estab-
lished by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST).17 The Clinical and Laboratory Standards
Institute (CLSI) has also provided susceptibility criteria for
Pseudomonas and Acinetobacter.18
2.2. Chromosomally mediated colistin resistance
The recent identiﬁcation of plasmid-mediated colistin resis-
tance mechanisms has extended our understanding of colistin
resistance that has been chromosomally mediated, with vertical
transmission and slow evolution.19–21 Colistin resistance is
thought to relate to lipopolysaccharide modiﬁcation via changes
in the mcrB gene and upregulation of PhoP/PhoQ.4,22–24 The
worldwide prevalence of resistance to polymyxins is about 10%
among Gram-negative bacteria and is highest in Mediterranean
countries and Southeast Asia.25
2.3. Plasmid-mediated colistin resistance
Plasmid-mediated colistin resistance encoded by mcr-1, a gene
of the phosphoethanolamine transferase enzyme family, was ﬁrst
documented in China during the routine surveillance of food
animals.20 A retrospective analysis of 1611 isolates of Escherichia
coli from chicken farms showed that the earliest mcr-1-harboring
isolate was from the 1980s when colistin was ﬁrst used for
livestock in China.26 Since then, mcr-1 has been identiﬁed in
isolates from humans, animals, and the environment in an
increasing number of countries (Table 1).20,21,26–104 In keeping
with other resistance mechanisms, mcr-1 is capable of travelling
with its human host; 10% of 38 travelers from India were found to
harbormcr-1 resistant E. coli in stool.55 The identiﬁcation ofmcr-1-
mediated colistin resistance in E. coli and Klebsiella pneumoniae in
pilgrims attending the annual Hajj indicates a risk for acquisition in
those attending mass gatherings.60
The initial description of mcr-1 was in 21% of healthy swine at
slaughter, 15% of marketed pork and chicken meat, and 1% of
hospitalized patients in China.20 The ﬁrst human isolate was
detected in E. coli in Latin America.46 In the SENTRY program, 5% of
clinical isolates of E. coli and K. pneumoniae were found to carry
mcr-1 resistance.105 K. pneumoniae with variant mcr-1 resistance
was also isolated from a rectal swab of an Italian child.34 Lastly,
resistant isolates carrying mcr-1 were described in 11 Salmonella
from clinical samples, food, and water in Portugal,106 and in
Shigella sonnei from Vietnam.96
Recently, mcr-2, another phosphoethanolamine transferase
plasmid-mediated colistin resistance gene, which shares 76.7%
nucleotide sequence homology tomcr-1, was isolated fromporcine
and bovine E. coli.21mcr-2 was identiﬁed in 21% of porcine colistin-
resistant E. coli in Belgium compared with 13% with mcr-1.21
The co-localization of mcr-1 with other resistance mechanisms
highlights the fact that discussions regarding the stewardship of
antibiotics across the OneHealth platform are not only pertinent to
antibiotics of last resort such as colistin, but also to more
commonly used antibiotics. There have been a number of reportsof co-localization ofmcr-1with carbapenemases and/or extended-
spectrum b-lactamase (ESBL); mcr-1 and blaNDM-5, a metallo-b-
lactamase, were transferred by an IncX3-X4 hybrid plasmid.54 A
similar ﬁnding was reported from a patient with a urinary tract
infection in the USA.65 mcr-1 has also been found to be associated
with ESBL-producing isolates bearing blaCTX-M-1 and a human
isolate with a blaKPC-2 carbapenemase gene.
37,81,92,98 In addition,
the mcr-1 gene co-localizes with multiple plasmid replicon types:
IncI2, IncHI2, IncP, IncFIP, and IncX4.43,81,107 These plasmids are
associated with resistance to quinolones and may acquire genes
conferring resistance to cephalosporin (blaCTX-M-14) and fosfomy-
cin (fosA3).108
The coexistence of mcr-1 with other resistance genes indicates
the existence of different pathways for the horizontal transmission
of colistin resistance.37 One isolate had blaNDM-9, fosA3, rmtB,
blaCTX-M-65, and ﬂoR thus conﬁrming resistance to carbapenems,
fosfomycin, aminoglycoside, cephalosporin, and ﬂorfenicol, re-
spectively.109 Resistant mcr-1 isolates to colistin, polymyxin B,
cephalosporin, gentamicin, and ciproﬂoxacin are thought to have
been transmitted from animals to humans.90 The coexistence of
these genes with high potential of spread is of great concern. It is
also important to keep in mind that these genes may be present in
strains that are relatively susceptible to other antibiotics, but as
they are reported as susceptible, colistin resistance is unlikely to be
routinely tested for.
3. Avoiding the blame game
Due to the status of colistin as the ‘antibiotic of last resort’ for
Gram-negative bacteria in humans, its use across the One Health
platform has come under intense scrutiny, and a climate of blame
has been generated, mainly directed towards farmers and
veterinarians.110,111 It is assumed that plasmid-mediated colistin
resistance moved from animals to humans, based on the fact that
mcr-1 and mcr-2 predominate in animals and were ﬁrst described
in animals, which as a group, consume the largest volume of that
antibiotic.28
However, the intense overuse and misuse of antibiotics such as
colistin across the One Health platform is driving selection
pressure, and it is therefore a collective, uniﬁed reduction in total
antibiotic use that must be focused upon.112 The human
consumption of colistin is itself a marker of overuse and misuse
of all antibiotics, which have systematically been rendered
ineffective by stepwise selection out of increasingly resistant
bacteria, resulting in the need to use ‘the last man standing’, i.e.,
colistin.
In livestock, colistin (and the vast majority of total antibiotic
use) has historically spoken to a simple need: an expanding global
population that requires food security in terms of animal
protein.113 To ensure this, sub-therapeutic concentrations of
antibiotics have been used for decades to promote animal growth,
and treatment doses are used for large-scale prophylaxis
(metaphylaxis) to protect healthy feed animals from infection.
In contrast, much smaller volumes are used for the individual
treatment of sick animals.114 Approximately 12 000 tons of colistin
is estimated to be used per year in 2015 in food production, with
consumption expected to rise to 16 500 tons by 2021.20 [4_TD$DIFF] These
volumes may be underestimates because surveillance data are
lacking for many countries.
The key to unlocking this conundrum is preventing infection in
humans and animals to reverse the continued reliance on
antibiotics to perform the task that tackling the social determi-
nants of infection would achieve. In human public health, this
relates to the provision of clean water and sanitation to reduce
diarrheal diseases, ensuring global access to immunization against
bacterial and viral illnesses that drive the use of antibiotics, and the
Table 1
Countries reporting plasmid-mediated colistin resistance encoded by mcr-1
Country Reference Year of sample/publication Ref.
Food animals and other animals
Algeria Chicken 2012 93
Argentina Kelp gulls 2012 103
Belgium Porcine and bovine (diarrhea) 2011–12 56
Belgium Porcine and bovine (diarrhea) 2011–12 21
Brazil Poultry and swine 2000–16 27, 45
Canada Ground beef 2010 104
China Swine 2011–14 20
China Chicken 1980–2014 26
China Chicken 2014 109
China Cats and dogs 2015 90
Denmark Imported chicken meat 2012–14 97
Egypt Bovine (subclinical mastitis) 2014 51
England and Wales Poultry meat 2012–15 43
England Swine 2014–15 101
Estonia Pig slurry 2016 66
European collection Bovine and swine digestive infections 2004–14 61
France Live stock (swine, broiler, turkey) 2007–14 35
France Veal calves 2005–14 98
France Poultry, sausage 2013 99
Germany Swine (R253, V163, 112065) 2010 37
Germany Poultry 2016 63
Germany Livestock 2010–15 80
Japan Cattle (mastitis) and swine (septicemia) 2007–14 47, 48
Laos Swine 2012 93
Lithuania European herring gull 2016 102
Malaysia Swine, chicken, 2013 94, 84, 50
Netherlands Retail chicken meat (at supermarkets) 2009–14 28, 29
Portugal Retail meat 2011–12 42
Portugal Food samples 2011 84
South Africa Poultry 2016 38–40
South Korea Livestock 2013 and 2015 69
Spain Poultry and swine 2016 32
Switzerland Poultry 2016 79
Taiwan Humans and retail meats 2016 49
Taiwan Retail meat (beef, chicken, pork) 2012–13, 2015 49
Tunisia Chicken farms 2016 53
USA Swine 2016 62
Venezuela Swine 2015 54
Vietnam Swine 2014–15 95
Vietnam Swine and chicken 2013–14 100
Humans
Argentina Human 2016 46
Bahrain Bed sore and urine 2015 70
Cambodia Feces of a child 2012 92
Canada Urine from a returning traveler 2016 73
Canada Gastrostomy tube 2011 104
China Hospitalized patients 2011–14 20
China Stool 2011–12 77
China Human microbiome 2011 84, 86, 89
China Blood, urine, peritoneal ﬂuid 2014–15 85
China Respiratory isolates 2015 87
China Human samples 2014 88
China Urine and blood 2015 90
China Human isolates 2016 91
Denmark Blood 2015 97
Ecuador Peritoneal ﬂuid 2016 64
Egypt Clinical isolate 2016 52
England and Wales Humans 2012–15 43
Germany Single wound infection 2010 37
Hong Kong Urine, blood, and stool samples 2015–16 74
India Travelers 2015 55
Italy Hospitalized patients 2012–15 33
Italy Surveillance rectal swab of a leukemic child 2012–15 34
Laos Human 2012 93
Malaysia Poultry meat; swine; human (urine) 2013 50
Netherlands Fecal samples of healthy travelers 2010–12 71
Netherlands Hospitalized patients 2016 30
Nigeria Patient 2012 93
Poland Hospitalized patient 2015 41
Saudi Arabia Pilgrims 60
Saudi Arabia Blood 2012 70
Singapore Urine 2016 75
South Africa Hospitalized and community patients 2014–16 25, 40
Spain Clinical isolates 2012–15 31
Switzerland Urinary isolates 2016 72
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Table 1 (Continued )
Country Reference Year of sample/publication Ref.
Switzerland Blood 2016 82
Switzerland Blood 2016 83
Taiwan Humans 2010, 2012, 2014 49
Thailand Human 2012 93
United Arab Emirates Blood 2013 70
USA Urine 2016 44
USA Stool of pediatric patient 2016 58
USA Urine 2016 59
USA Urine 2014 65
Venezuela Human isolates 2015 54
Vietnam Stool 2008 96
Environment
Switzerland River water and imported vegetable samples 2016 36
China Hospital sewage 2016 57
Malaysia Water 50
France Boot swab from broiler farm 2013 99
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in healthcare establishments to prevent healthcare-associated
infections and the transmission of bacteria between patients
through poor hand hygiene.
Experience from the European Union since the ban on animal
growth promoters (AGP) in 2006 suggests that improving
biosecurity, biosafety, and the diet of livestock could render the
need for AGPs obsolete and signiﬁcantly reduce the need for
metaphylaxis, reserving it for the protection of healthy animals
only when others in the group become sick.114 Furthermore,
cleaning and disinfection between meat production cycles is an
important public health intervention in food production to limit
the spread and accumulation of resistance genes in the following
cycles.115–117 Lastly, the companion animal–human axis should
not be ignored. A study by Zhang et al. has recently highlighted the
transmission of E. coli carryingmcr-1 between companion animals
and humans.90
4. How should we respond?
According to the US Centers for Disease Control and Prevention
(CDC), ‘‘the One Health concept recognizes that the health of
humans is connected to the health of animals and the environ-
ment’’.118 Another deﬁnition is ‘‘the collaborative effort of multiple
disciplines working locally, nationally, and globally to attain
optimal health for people, animals and our environment’’.119 The
One Health program relies on three pillars: human health,
livestock or aquaculture, and environmental health.120 Under-
standing the relative importance of the contribution of each
component is important in tackling antimicrobial resistance.120
A One Health approach to decrease the consumption of all
antibiotics is the goal.121,122 To protect food security, phasing out
antibiotic use for AGP and metaphylaxis in favor of heightened
infection prevention and nutrition interventions will take time.
However, critical antibiotics required for human use, such as
colistin, should be protected by an immediate cessation of use in
livestock, as has been announced by the Responsible Use of
Medicines in Agriculture (RUMA) alliance123 and China.124 This
must be done in concert with restrictions in human use: restricting
colistin for deﬁnitive treatment based on susceptibility testing, or
to empirical use in clearly deﬁned circumstances, coupled with
attention to pharmacokinetics and pharmacodynamics to ensure
optimal dosing, must be part of every country’s national action
plan. Ambitious targets should be set by each country to reduce
overall consumption.125
In terms of dosing, high doses of up to 720 mg (9million IU) per
day are employed,126,127 and the need for a loading dose has been
highlighted.128,129 Under-dosing colistin in patients with criticalillness, burns, renal failure, and obesity risks the emergence of
resistance.130 Resistant strains have been reported in burn
patients,130 and critically ill patients on continuous venovenous
hemodiaﬁltration require higher doses.131 There have been no
prospective studies evaluating the optimal dosing of colistin to
limit side effects and provide the best bactericidal effect. It is feared
that doses that result in sub-optimal bactericidal colistin
concentrations may lead to the selection of resistant bacte-
ria.132,133 In a retrospective observational study of 72 patients with
MDR Gram-negative pneumonia, the clinical cure rate was 55% in
those receiving a regular dosing regimen compared to 67% in those
receiving a loading dose and high-dose maintenance regimen.134
As with other antibiotics, prior use of colistin is itself a risk
factor for the development of resistance.135 In a study of
20 patients, both colistin-susceptible and colistin-resistant Aci-
netobacter from the same patients were found to be highly related
by pulsed-ﬁeld gel electrophoresis (PFGE), indicating the develop-
ment of resistance during colistin treatment.136 In a further study
of 41 colistin-resistant isolates, colistin was the only independent
risk factor for such resistance.137 The enteral use of colistin for
selective gastrointestinal decontamination has been associated
with the emergence of colistin resistance.138 However, this
resistance is thought to be secondary to sub-therapeutic colistin
doses.139,140
Ultimately, the action we take to protect human health, which
relies just as much on food security as it does on antibiotics to treat
serious bacterial infections, must be translatable to all antibiotics
(and indeed all antimicrobials), including the new antibiotics to
come. The proposed global stewardship framework, which will lay
out howwe steward a new antibiotic to ensure equity of access and
deﬁne the working parameters for how it should be used, must be
enforceable and countries must be accountable for their protec-
tion. A United Nations-led coordinating mechanism, as agreed at
the UN General Assembly in September 2016, provides an
opportunity to deﬁne a true One Health approach to antibiotic
consumption and to set upmonitoring and evaluationmechanisms
to ensure countries comply.141 This will be essential if we are to
conserve colistin pending the development of new antibiotics to
treat MDR Gram-negative bacteria.
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